Candida Albicans Secreted Aspartyl Proteinases in Virulence and Pathogenesis

Overview

Journal Microbiol Mol Biol Rev

Publisher American Society for Microbiology

Specialty Microbiology

Date 2003 Sep 11

PMID 12966142

Citations 439

Authors

Julian R Naglik

Stephen J Challacombe

Bernhard Hube

Affiliations

Soon will be listed here.

Abstract

Candida albicans is the most common fungal pathogen of humans and has developed an extensive repertoire of putative virulence mechanisms that allows successful colonization and infection of the host under suitable predisposing conditions. Extracellular proteolytic activity plays a central role in Candida pathogenicity and is produced by a family of 10 secreted aspartyl proteinases (Sap proteins). Although the consequences of proteinase secretion during human infections is not precisely known, in vitro, animal, and human studies have implicated the proteinases in C. albicans virulence in one of the following seven ways: (i) correlation between Sap production in vitro and Candida virulence, (ii) degradation of human proteins and structural analysis in determining Sap substrate specificity, (iii) association of Sap production with other virulence processes of C. albicans, (iv) Sap protein production and Sap immune responses in animal and human infections, (v) SAP gene expression during Candida infections, (vi) modulation of C. albicans virulence by aspartyl proteinase inhibitors, and (vii) the use of SAP-disrupted mutants to analyze C. albicans virulence. Sap proteins fulfill a number of specialized functions during the infective process, which include the simple role of digesting molecules for nutrient acquisition, digesting or distorting host cell membranes to facilitate adhesion and tissue invasion, and digesting cells and molecules of the host immune system to avoid or resist antimicrobial attack by the host. We have critically discussed the data relevant to each of these seven criteria, with specific emphasis on how this proteinase family could contribute to Candida virulence and pathogenesis.

Citing Articles

Candida albicans aspartyl protease (Sap6) inhibits neutrophil function via a "Trojan horse" mechanism.

Zawrotniak M, Satala D, Juszczak M, Bras G, Rapala-Kozik M Sci Rep. 2025; 15(1):6946.

PMID: 40011643 PMC: 11865311. DOI: 10.1038/s41598-025-91425-x.

Different essential oils can inhibit Candida albicans biofilm formation on acrylic resin by suppressing aspartic proteinase: In vitro and in silico approaches.

Sagsoz N, Guven L, Gur B, Sezer C, Cengiz M, Orhan F Clin Oral Investig. 2025; 29(2):94.

PMID: 39875714 DOI: 10.1007/s00784-024-06039-w.

In vitro evaluation of silver-zinc oxide-eugenol nanocomposite for enhanced antimicrobial and wound healing applications in diabetic conditions.

Nagaiah H, Samsudeen M, Augustus A, Shunmugiah K Discov Nano. 2025; 20(1):14.

PMID: 39847138 PMC: 11757845. DOI: 10.1186/s11671-025-04183-0.

Exploring the anti-biofilm and gene regulatory effects of anti-inflammatory drugs on Candida albicans.

Yazdanpanah S, Shafiekhani M, Emami M, Khodadadi H, Pakshir K, Zomorodian K Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39731595 DOI: 10.1007/s00210-024-03727-y.

Exploring the Biology, Virulence, and General Aspects of .

Gomez-Gaviria M, Baruch-Martinez D, Mora-Montes H Infect Drug Resist. 2024; 17:5755-5773.

PMID: 39722735 PMC: 11669290. DOI: 10.2147/IDR.S497862.

References

Togni G, Sanglard D, Falchetto R, Monod M . Isolation and nucleotide sequence of the extracellular acid protease gene (ACP) from the yeast Candida tropicalis. FEBS Lett. 1991; 286(1-2):181-5. DOI: 10.1016/0014-5793(91)80969-a. View

Ross I, De Bernardis F, EMERSON G, Cassone A, Sullivan P . The secreted aspartate proteinase of Candida albicans: physiology of secretion and virulence of a proteinase-deficient mutant. J Gen Microbiol. 1990; 136(4):687-94. DOI: 10.1099/00221287-136-4-687. View

Schaller M, Schafer W, Korting H, Hube B . Differential expression of secreted aspartyl proteinases in a model of human oral candidosis and in patient samples from the oral cavity. Mol Microbiol. 1998; 29(2):605-15. DOI: 10.1046/j.1365-2958.1998.00957.x. View

Borg M, Watters D, Reich B, Ruchel R . Production and characterization of monoclonal antibodies against secretory proteinase of Candida albicans CBS 2730. Zentralbl Bakteriol Mikrobiol Hyg A. 1988; 268(1):62-73. DOI: 10.1016/s0176-6724(88)80116-0. View

Tsushima H, Mine H, Kawakami Y, Hyodoh F, Ueki A . Candida albicans aspartic proteinase cleaves and inactivates human epidermal cysteine proteinase inhibitor, cystatin A. Microbiology (Reading). 1994; 140 ( Pt 1):167-71. DOI: 10.1099/13500872-140-1-167. View

De Bernardis F, Boccanera M, Rainaldi L, Guerra C, Quinti I, Cassone A . The secretion of aspartyl proteinase, a virulence enzyme, by isolates of Candida albicans from the oral cavity of HIV-infected subjects. Eur J Epidemiol. 1992; 8(3):362-7. DOI: 10.1007/BF00158569. View

Stewart K, Abad-Zapatero C . Candida proteases and their inhibition: prospects for antifungal therapy. Curr Med Chem. 2001; 8(8):941-8. DOI: 10.2174/0929867013372698. View

Krause R, Schwab E, Bachhiesl D, Daxbock F, Wenisch C, Krejs G . Role of Candida in antibiotic-associated diarrhea. J Infect Dis. 2001; 184(8):1065-9. DOI: 10.1086/323550. View

Wu T, Samaranayake L . The expression of secreted aspartyl proteinases of Candida species in human whole saliva. J Med Microbiol. 1999; 48(8):711-720. DOI: 10.1099/00222615-48-8-711. View

10.

White T, Pfaller M, Rinaldi M, Smith J, Redding S . Stable azole drug resistance associated with a substrain of Candida albicans from an HIV-infected patient. Oral Dis. 1997; 3 Suppl 1:S102-9. DOI: 10.1111/j.1601-0825.1997.tb00336.x. View

11.

Miyasaki S, Hicks J, Greenspan D, Polacheck I, MacPhail L, White T . The identification and tracking of Candida albicans isolates from oral lesions in HIV-seropositive individuals. J Acquir Immune Defic Syndr (1988). 1992; 5(10):1039-46. View

12.

Soll D, Morrow B, Srikantha T . High-frequency phenotypic switching in Candida albicans. Trends Genet. 1993; 9(2):61-5. DOI: 10.1016/0168-9525(93)90189-O. View

13.

Sobel J . Pathogenesis and treatment of recurrent vulvovaginal candidiasis. Clin Infect Dis. 1992; 14 Suppl 1:S148-53. DOI: 10.1093/clinids/14.supplement_1.s148. View

14.

Kimura L, Pearsall N . Adherence of Candida albicans to human buccal epithelial cells. Infect Immun. 1978; 21(1):64-8. PMC: 421958. DOI: 10.1128/iai.21.1.64-68.1978. View

15.

Caro L, Tettelin H, Vossen J, Ram A, van den Ende H, Klis F . In silicio identification of glycosyl-phosphatidylinositol-anchored plasma-membrane and cell wall proteins of Saccharomyces cerevisiae. Yeast. 1998; 13(15):1477-89. DOI: 10.1002/(SICI)1097-0061(199712)13:15<1477::AID-YEA184>3.0.CO;2-L. View

16.

Fusek M, Smith E, Monod M, Dunn B, Foundling S . Extracellular aspartic proteinases from Candida albicans, Candida tropicalis, and Candida parapsilosis yeasts differ substantially in their specificities. Biochemistry. 1994; 33(32):9791-9. DOI: 10.1021/bi00198a051. View

17.

Sweet S . Selection and pathogenicity of Candida albicans in HIV infection. Oral Dis. 1997; 3 Suppl 1:S88-95. DOI: 10.1111/j.1601-0825.1997.tb00383.x. View

18.

Morrow B, Srikantha T, Anderson J, Soll D . Coordinate regulation of two opaque-phase-specific genes during white-opaque switching in Candida albicans. Infect Immun. 1993; 61(5):1823-8. PMC: 280771. DOI: 10.1128/iai.61.5.1823-1828.1993. View

19.

Whelan W, Kirsch D, Kwon-Chung K, Wahl S, Smith P . Candida albicans in patients with the acquired immunodeficiency syndrome: absence of a novel of hypervirulent strain. J Infect Dis. 1990; 162(2):513-8. DOI: 10.1093/infdis/162.2.513. View

20.

von Heijne G . Signal sequences. The limits of variation. J Mol Biol. 1985; 184(1):99-105. DOI: 10.1016/0022-2836(85)90046-4. View